NMT Pharma of Singapore In-licenses Cancer Drug from US's CAO Pharma
April 11, 2016 at 04:11 AM EDT
Singapore's NMT Pharma in-licensed worldwide rights to a cancer drug co-developed by CAO Pharma of Houston, Texas and NMT. CAO developed CZ-48, an analogue of camptothecin, to become active only within tumors. A well-known cytotoxic agent, camptothecin is used in traditional Chinese medicine and is derived from the bark of the camptotheca tree. Other variants of the drug are the approved drugs topotecan and irinotecan. NMT is a CRO with technology that improves the bioavailability of drug candidates. Financial details were not disclosed. More details.... Share this with colleagues: // //